Abstract
BackgroundThere have been few studies of pulmonary actinomycosis, which is an uncommon anaerobic infection. Consequently, the optimal therapeutic regimen, appropriate duration of treatment, long-term prognosis, and factors predicting prognosis are not well established.MethodsWe retrospectively reviewed the medical records of histopathologically confirmed cases of pulmonary actinomycosis seen between November 2003 and December 2012.ResultsThe study included 68 patients with a mean age of 58.4 ± 11.6 years. Of the 68, initial surgery was performed in 15 patients (22.1%), while the remaining 53 (77.9%) received antibiotic therapy initially. In the initial antibiotic group, 45/53 (84.9%) were cured without relapse (median antibiotic duration 5.3 months). 5/53 (9.4%) patients were refractory medically (median antibiotic duration 9.7 months), and 3/53 (5.7%) experienced a recurrence (median time to relapse 35.3 months). In the initial surgery group, 14/15 (93.3%) were cured and treatment failure occurred in one (6.7%). In the multivariate analysis, the absence of an antibiotic response at 1 month was the only independent factor associated with a poor treatment outcome, with an adjusted odds ratio of 49.2 (95% CI, 3.34–724.30). There was no significant difference in treatment outcome based on the size of the parenchymal lesion, comorbidities, whether intravenous antibiotics were used, antibiotic therapy duration, or whether the initial treatment was surgical.ConclusionsAntibiotic treatment with or without surgery was effective for treatment of pulmonary actinomycosis. Nevertheless, treatment failure or recurrence occurred in a considerable proportion of patients, especially those resistant to the initial antibiotic treatment.
Highlights
There have been few studies of pulmonary actinomycosis, which is an uncommon anaerobic infection
Patients with pulmonary actinomycosis are treated with high-dose intravenous (IV) penicillin at a dose of 18–24 million units daily for 2–6 weeks, followed by oral penicillin or amoxicillin for 6–12 months [2]
A recent study showed that medical treatment failure can occur in patients receiving appropriate antibiotics for pulmonary actinomycosis [6]
Summary
There have been few studies of pulmonary actinomycosis, which is an uncommon anaerobic infection. Actinomycosis is a chronic, slowly progressive granulomatous disease caused by filamentous Gram-positive anaerobic or microaerophilic bacteria of the family Actinomycetaceae (genus Actinomyces) [1]. These normally colonize the mouth, colon, and vagina [2]. A recent study showed that medical treatment failure can occur in patients receiving appropriate antibiotics for pulmonary actinomycosis [6]. This is incompatible with the traditional concept of a medically treatable disease with a good prognosis [5]. No randomized controlled trial or large-scale retrospective study has compared antibiotic regimens or treatment modalities
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have